Markable coagulopathy in the patient with severe COVID-19

Abstract

The variative coagulation abnormalities with thrombotic and microvascular complications are distinguishing feature of the severe new coronavirus infection (COVID-19) pathogenesis. Abnormal coagulopathy is directly related to the risk of death in COVID-19 patients. In many patients with COVID-19, hemostasis disorders have been observed, which increase the risk of developing DIC (disseminated intravascular coagulation), thrombotic microangiopathy or antiphospholipid syndrome as a result of the pathogenetic factors combination: inflammatory response, endothelial dysfunction, increased platelet consumption, microvascular thrombosis. The mechanism of coagulopathy associated with COVID is still being found, COVID-associated coagulopathy exemplifies the potentiating multi-factor interactions between the immune system and the coagulation. We’re reporting a fatal case of 51-year-old male with COVID-19, complicated by severe acute respiratory syndrome (SARS) and severe thrombocytopenia, markedly enhanced fibrinolytic activity with skin-hemorrhagic syndrome, thrombotic complication (myocardial infarction), probably related to the DIC. This case demonstrates the need more basic and clinical research is warranted to further our understanding of the role of coagulation disorders mechanism in COVID-19 to prevent severe outcomes and mortality.